The investigational cell-based therapy NurOwn may slow disease progression in people with amyotrophic lateral sclerosis (ALS) who have less severe disease, according to analyses from a Phase 3 trial. Researchers’ analyses excluded patients with the lowest scores on the ALS Functional Rating Scale–Revised (ALSFRS-R) or in individual…
News
Early declines in neurofilament light chain (NfL), a biomarker of nerve cell damage, after treatment with tofersen may predict a slower disease progression over time in people with SOD1-associated amyotrophic lateral sclerosis (ALS). Patients who received tofersen early also experienced a significantly slower worsening of clinical function than…
Continuous monitoring of certain biomarkers in people with amyotrophic lateral sclerosis (ALS) may inform about the risk of disease progression and the response to edaravone, according to interim data from the ongoing REFINE-ALS biomarker study. Mitsubishi Tanabe Pharma America (MTPA), the developer of edaravone, recently shared these findings…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Stealth Biotherapeutics’ investigational therapy SBT-272 for the treatment of amyotrophic lateral sclerosis (ALS). Aimed at speeding the development of new treatments for rare, life-threatening diseases, orphan drug status offers regulatory support and certain financial incentives…
Four years after its discovery via an artificial intelligence (AI) platform, Verge Genomics will test its amyotrophic lateral sclerosis (ALS) treatment candidate VRG50635 — a PIKfyve inhibitor — in a first-in-human trial. The Phase 1 clinical trial (ISRCTN14792372), which is now enrolling participants, is being conducted at the…
CuATSM, a potential amyotrophic lateral sclerosis (ALS) therapy that’s now in clinical trials, may work by altering how certain cells in the brain generate energy, a new study suggests. Researchers say these findings may help to identify patients most likely to respond to the experimental treatment. “Screening patient derived…
Proposed updates to the National ALS Registry’s case-identification algorithm and classifications may help provide a better estimate of the prevalence of amyotrophic lateral sclerosis (ALS) in the U.S., a study reported. Under the revision, individuals previously classified as “possible ALS” cases and excluded from the registry would now…
Higher long-term exposure to certain forms of air pollution — specifically coarse particulate matter, such as that from traffic pollutants — significantly increases the risk of amyotrophic lateral sclerosis (ALS) in postmenopausal women, a study showed. “Although the effects noted within the current study are limited by sample size…
High total protein levels in the cerebrospinal fluid (CSF) — the liquid that surrounds the brain and spinal cord — are linked to shorter survival among amyotrophic lateral sclerosis (ALS) patients with limb-onset disease, a study showed. The researchers noted a similar association was found for high CSF…
Deep machine-learning models using neural networks — computer algorithms inspired in the biological networks of the human brain —may help to predict the course of amyotrophic lateral sclerosis (ALS), a new study reports. The models also consistently showed that a longer delay between disease onset and diagnosis is a…
Recent Posts
- Ahead of this year’s MDA Conference, association’s CEO speaks of ‘hope’
- Higher blood lactate levels tied to survival, weight changes in ALS
- AB Science adds new biomarker to Phase 3 masitinib ALS clinical trial
- ‘Early birds’ have significantly lower ALS risk than ‘night owls’: Study
- As my late husband’s ALS progressed, we kept our bucket list simple